RxDoctor Payments Data

Rohit Masih, MD

Internal Medicine · Minneapolis, MNNPI 1306206669

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (56.4%), travel and lodging and education — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Cvrx, Inc. at 57.8% of the total. 2025 is the largest year on record at $2,691, more than ten times the $88 reported in 2019. Among internal medicine clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,370in general payments, 2019–2025

Across 56 payments — averaging $95.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$3K
  • Abbott$1K
  • AstraZeneca$390
  • Johnson & Johnson$262
  • Pfizer$136
  • Amgen$111
  • plus $367 from 9 others

What the payments were for

  • Travel & lodging$1,86735%
  • Food & beverage$3,02956%
  • Education$4749%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,370 in reported general payments places this provider in the 95th percentile of 1,924 internal medicine providers in Minnesota.

See all internal medicine providers in Minnesota

Medicare billing

Part B allowed, 2024
$28,616
Medicare patients
112
Services billed
242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban24$12,899
JardianceEmpagliflozin14$8,040
Ezetimibe14$819
Hydralazine Hcl14$494
Metoprolol Succinate24$323
Atorvastatin Calcium21$205
Donepezil Hcl11$159
Losartan Potassium15$134
Levothyroxine Sodium11$112
Amlodipine Besylate15$63
Spironolactone15$52

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$136$12,89924 claims
Boehringer IngelheimJardiance$27$8,04014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,924 internal medicine providers in Minnesota.

Other internal medicine in Minneapolis

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →